Liver cancer (hepatocellular carcinoma)
Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)
Tecentriq is used to treat hepatocellular carcinoma (HCC) which is the most common form of liver cancer. Tecentriq is used together with a medicine called Avastin when the HCC is unable to be removed by surgery or has spread to other parts of the body.
How Tecentriq works
Tecentriq works by attaching to a protein in your body, called PD-L1, which is found on some tumour cells. When this happens Tecentriq helps the immune system to better identify the cancer cells and kill them.
How Avastin works
Avastin works by blocking an important growth factor called vascular endothelial growth factor or VEGF. This disrupts blood flow to the cancer, restricting the supply of nutrients that it needs to grow and spread.
Because Tecentriq and Avastin work in different ways, the two medicines complement each other when they are used to treat HCC.
Clinical Trial Data
The safety and efficacy of Tecentriq and Avastin for the treatment of HCC has been studied in a global, phase 3 trial called IMbrave150. The results of this study found that those taking Tecentriq plus Avastin had better progression-free survival and overall survival compared to those taking another medicine called sorafenib.
Keep in mind that everyone is different, and the response and benefit you may experience cannot be predicted. Ask your doctor about the clinical evidence for Tecentriq and Avastin and if the combination is right for you.
Possible side effects of Tecentriq and Avastin
All medicines can have side effects. You will find a list of known side effects in the respective Tecentriq and Avastin Consumer Medicine Information available via links below.
Talk to your doctor to see if Tecentriq and Avastin are right for you.
How to access Tecentriq and Avastin
Tecentriq and Avastin are not funded by PHARMAC. This means that you will need to pay for both medicines at a private treatment centre. If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover cancer treatment, surgery, tests and appointments.
To help with the cost of treatment with Tecentriq and Avastin, Roche has created a Cost Share Programme, to help make it more affordable to patients in New Zealand.
The Cost Share Programme is designed to reduce the cost of the medicines, and caps the number of treatment cycles that need to be paid for. This means that you’ll know the maximum amount you need to pay over a certain period of time before you go onto treatment. Other costs, however, such as doctor fees and administration costs, will still apply.
Ready to take the next step?
Because every situation is different, it’s important to speak to your medical team to find out if Tecentriq and Avastin are right for you.
We’ve put together a discussion guide to help you begin a conversation with your doctor. Print it off, take it along to your next appointment, and take notes in the spaces provided.
Talking to your doctor about Tecentriq and Avastin
To help you in this process, we’ve put together a discussion guide to help you begin a conversation with your doctor. Print it off, take it along to your next appointment, and take notes in the spaces provided.
For further information about private treatment providers click here.
You can also talk to your current doctor about referral to a private doctor or treatment centre.
To learn more about how medicines become available in New Zealand, click here.
These resources contain important safety and side effect information. Please keep in mind that these are not intended to replace medical advice from a doctor or other healthcare professionals.